Clinical Trials Logo

SLE clinical trials

View clinical trials related to SLE.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06182969 Not yet recruiting - SLE Clinical Trials

A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.

Start date: December 2023
Phase: Phase 1/Phase 2
Study type: Interventional

To evaluate the safety, tolerability, pharmacokinetics and pharmacokinetics of multi-dose APG-2575 in mild-to-moderate systemic lupus erythematosus (SLE).

NCT ID: NCT05479071 Not yet recruiting - SLE Clinical Trials

Relation of Antibodies Against Oxidized Low Density Lipoproteins to Disease Activity and Cardiovascular Affection in Systemic Lupus.

Start date: September 1, 2022
Phase:
Study type: Observational [Patient Registry]

The aim of this study is to correlate the autoantibody against oxidized LDL with disease activity and cardiovascular affection in patients with SLE.

NCT ID: NCT05161988 Not yet recruiting - SLE Clinical Trials

Serum IL 26 as a Marker of Disease Activity in SLE

Start date: December 10, 2021
Phase:
Study type: Observational

Assessment of serum Interleukin 26 level in SLE patients and compare it with healthy controls. Association of serum interleukin 26 with SLE activity and severity.

NCT ID: NCT04517240 Not yet recruiting - SLE Clinical Trials

A Study on Protein Losing Enteropathy In Systemic Lupus Erythematosus

Start date: October 1, 2020
Phase:
Study type: Observational

The aim of the current study is to investigate if there is GIT involvement in pt's with SLE particularly protein losing enteropathy also its prevalence among the studied cases and it's relation to disease activity .

NCT ID: NCT04234633 Not yet recruiting - SLE Clinical Trials

Effect of Gender on Clinical Presentation of SLE ِAt Assiut University Hospitals

Start date: March 2020
Phase:
Study type: Observational

The investigators aim to compare the clinical characteristics and outcomes of SLE between male and female Egyptian patients at Assuit University Hospital.

NCT ID: NCT03984227 Not yet recruiting - SLE Clinical Trials

New Signaling Pathway Targeting Systemic Lupus Erythematosus

Start date: July 2019
Phase:
Study type: Observational

Systemic lupus erythematosus is inflammatory autoimmune disease that affects over one million people in the United States. It has a higher prevalence and incidence rate among women compared with men, and among African Americans compared with Caucasians. Despite advances in treatment, standardized mortality rates in SLE remain three times higher than in the general population. The risk of mortality is significantly increased because of renal disease, cardiovascular disease, and infection.The etiology of SLE is multifactorial, with genetic predisposition, environmental factors and epigenetic alterations are involved. However, the molecular mechanisms underlying this systemic autoimmune response remain largely unknown. A key issue in the pathogenesis of lupus is how intracellular antigens become exposed and targeted by the immune system.